Clinical Trial Results:
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant
Hypertension
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in
Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with
Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311)
Summary
|
|
EudraCT number |
2006-001898-25 |
Trial protocol |
SE DK DE GB ES IT |
Global completion date |
16 Jan 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Jan 2017
|
First version publication date |
05 Jan 2017
|
Other versions |
|
Summary report(s) |
DAR-311_Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.